Gilead Sciences Newswire

Comprehensive Real-Time News Feed for Gilead Sciences.

Results 1 - 20 of 1,256 in Gilead Sciences

  1. CohBar, Inc. Announces Publication of Preclinical Proof-of-Principle...Read the original story

    3 hrs ago | Freshnews

    ... Kenneth Cundy, former Chief Scientific Officer at Xenoport, Inc. and Senior Director of Biopharmaceutics at Gilead Sciences, Inc. CohBar (TSXV: COB.U) is the leader in the research and development of mitochondria-based therapeutics (MBTs), a new ...

    Comment?

  2. Budget in India Takes Incremental Approach, Auto Sales RiseRead the original story

    6 hrs ago | Ticker

    ... Ltd jumped 4% to 1,426.55 after the pharmaceutical ingredients maker signed an agreement with U.S.-based Gilead Sciences, Inc. to manufacture and sell generic versions of its chronic hepatitis C medicines. Olacabs , the smart phone app for personal ...

    Comment?

  3. Yale report: Millions of people with hepatitis C blocked from...Read the original story

    10 hrs ago | Medical News Today

    ... on the market, costs $1000 a pill or $84,000 for a full course of treatment in the USA. Though its maker, Gilead Sciences Inc., has discounted the price for low- and middle-income countries in some cases, the price is still too high in countries ...

    Comment?

  4. UPDATE 1-India's Natco Pharma ties up with Gilead on hepatitis C drugsRead the original story

    11 hrs ago | Reuters

    India's Natco Pharma Ltd said on Monday it has agreed a deal with Gilead Sciences Inc to supply generic copies of the U.S. drugmaker's chronic hepatitis C medicines, including $1,000-a-pill drug Sovaldi, in 91 developing nations. Natco, a mid-sized player in India's crowded pharmaceutical industry, is the latest generic drugmaker to team up with Gilead on Sovaldi, having previously attempted to block the U.S. firm from getting a patent for the breakthrough drug in India in the hope of producing a cheaper version on its own.

    Comment?

  5. India's Natco Pharma ties up with Gilead on hepatitis C drugsRead the original story

    14 hrs ago | Reuters

    India's Natco Pharma Limited said on Monday it signed a licensing deal with Gilead Sciences Inc to make and sell generic versions of the U.S. drugmaker's chronic hepatitis C medicines. Drugs under the deal include sofosbuvir, a combination of ledipasvir and sofosbuvir, and GS-5816, which is in late-stage clinical trials, Natco said in a statement.

    Comment?

  6. Assyrians in San Jose hold prayer vigil for embattled countrymen in SyriaRead the original story w/Photo

    Friday | SiliconValley.com

    ... in San Jose.'' One local Assyrian attending the prayer vigil was Thuraieh Khayou, a research associate for Gilead Sciences in Foster City, where she commutes each Monday from her home in Turlock. She said her mother and father both came from small ...

    Comment?

  7. Hepatitis-drug guidelines will be revisitedRead the original story w/Photo

    Friday | Star Tribune

    ... policy. Health insurers and government programs have been grappling with the cost of the pills. Made by Gilead Sciences Inc. and AbbVie Inc., they offer higher cure rates and fewer side effects than older medicines, though their $1,000-a-day price ...

    Comment?

  8. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Friday | Business Wire

    Gilead publiceert SVR12 genezingsratio's van het fase 3 evaluatieonderzoek van Harvoni voor de behandeling van chronische hepatitis C bij patinten geconfecteerd met HIV )--Gilead Sciences, Inc. heeft vandaag de resultaten bekendgemaakt van een fase 3-onderzoek, ION-4, ter beoordeling van het eenmaal daagse regime Harvoni --This A.M.BestTV episode looks at a new McKinsey & Company survey, which shows that charitable giving by the insurance industry has risen by 15% since 2011.

    Comment?

  9. Bogus news snarls Immunovaccine stockRead the original story w/Photo

    Friday | The Chronicle Herald

    ... issued by the Halifax-based company, announced the firm had entered into a co-development agreement with Gilead Sciences, Inc. and received fast-track approval from the U.S. Food and Drug Administration for clinical trials of anthrax and Ebola ...

    Comment?

  10. Gilead Sciences Inc v. LeeRead the original story w/Photo

    Thursday Feb 26 | FindLaw

    GILEAD SCIENCES, INC., Plaintiff-Appellant v. Michelle K. LEE, Deputy Director, United States Patent and Trademark Office, Acting Under Secretary of Commerce for Intellectual Property, Defendant-Appellee.

    Comment?

  11. Doctor Panel to Weigh Hepatitis C Drugs' Costs in GuidelinesRead the original story

    Friday Feb 27 | The Washington Post

    ... policy. Health insurers and government programs have been grappling with the cost of the pills. Made by Gilead Sciences Inc. and AbbVie Inc., they offer higher cure rates and fewer side effects than older medicines, though their $1,000-a-day price ...

    Comment?

  12. Gilead Announces Phase 3 Results For Investigational Once-Daily...Read the original story

    Thursday Feb 26 | BioSpace

    ... to Be Non-Inferior with Improved Renal and Bone Parameters Compared to StribildA - SEATTLE--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48-week results from two Phase 3 studies (Studies 104 and 111) evaluating its ...

    Comment?

  13. With Product Sales And Drugs In The Pipeline, The Future Looks Bright For Gilead SciencesRead the original story w/Photo

    Friday Feb 27 | Seeking Alpha

    Gilead Sciences' current drugs are performing well; however, all good things must come to an end. In Gilead's case, expiration of patents and new advancements in pharmacology will eventually bring them to an end.

    Comment?

  14. What the pros like about ETFs - and what they don'tRead the original story w/Photo

    Friday Feb 27 | The Globe and Mail

    ... in biotech and pharmaceutical companies listed on the Nasdaq, such as Biogen IDEC Inc., Celegene Corp., Gilead Sciences Inc. and Amgen Inc. Over the past five years the Nasdaq Biotech ETF has tripled in value while the broader Nasdaq 100 has lagged, ...

    Comment?

  15. Gilead Holds Cash Overseas to Save Billions on TaxesRead the original story

    Thursday Feb 26 | BioSpace

    Gilead Sciences Inc., whose $1,000-a-pill hepatitis C treatment is one of the world's most expensive drugs, is avoiding billions of dollars in U.S. taxes by booking profits overseas. The company reported foreign income before taxes of $8.2 billion for 2014, earning more in non-U.S. profits than it recorded in non-U.S. sales.

    Comment?

  16. Gilead's Harvoni Achieves 96% Cure Rate in Patients With Hepatitis C and HIVRead the original story

    Thursday Feb 26 | BioSpace

    Gilead Sciences, Inc. today announced results from a Phase 3 study, ION-4, evaluating the once-daily single tablet regimen HarvoniA for the treatment of genotypes 1 or 4 chronic hepatitis C virus infection among patients co-infected with HIV. In the trial, 96 percent of HCV patients achieved a sustained virologic response 12 weeks after completing therapy .

    Comment?

  17. Gilead avoids billions in taxes on expensive drugsRead the original story w/Photo

    Thursday Feb 26 | SFGate

    An undated handout photo of Sovaldi, a hepatitis C treatment made by Gilead Sciences that typically costs $84,000 and cures around 90 percent of patients who take it. A Washington advocacy effort has sprung up overnight, largely devoted to objecting to the cost of the medication, and members of Congress have started a joint investigation into how Gilead Sciences settled on its price.

    Comment?

  18. Gilead avoids billions in U.S. taxes on pillRead the original story w/Photo

    Thursday Feb 26 | Salt Lake Tribune

    Washington a Gilead Sciences Inc., whose $1,000-a-pill hepatitis C treatment is one of the world's most expensive drugs, is avoiding billions of dollars in U.S. taxes by booking profits overseas. The company reported foreign income before taxes of $8.2 billion for 2014, earning more in non-U.S. profits than it recorded in non-U.S. sales.

    Comment?

  19. Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni...Read the original story

    Thursday Feb 26 | Information Technology

    Gilead Sciences, Inc. today announced results from a Phase 3 study, ION-4, evaluating the once-daily single tablet regimen Harvoni for the treatment of genotypes 1 or 4 chronic hepatitis C virus infection among patients co-infected with HIV. In the trial, 96 percent of HCV patients achieved a sustained virologic response 12 weeks after completing therapy .

    Comment?

  20. Gilead Press Release Regarding Phase 3 Harvoni StudyRead the original story

    Thursday Feb 26 | Benzinga

    Gilead Sciences, Inc. today announced results from a Phase 3 study, ION-4, evaluating the once-daily single tablet regimen Harvoni for the treatment of genotypes 1 or 4 chronic hepatitis C virus infection among patients co-infected with HIV. In the trial, 96 percent of HCV patients achieved a sustained virologic response 12 weeks after completing therapy .

    Comment?